Skip to main content
Erschienen in: Diabetologia 6/2016

07.04.2016 | Commentary

The liver in focus

verfasst von: Michael Roden

Erschienen in: Diabetologia | Ausgabe 6/2016

Einloggen, um Zugang zu erhalten

Excerpt

The liver is not only responsible for handling carbohydrates and lipids, but is also a key signalling organ, producing hormones (hepatokines) and receiving signals from other tissues. Nevertheless, studies on the liver in diabetes mellitus have focused on its role in alterating glucose fluxes (Fig. 1). Although the association of non-alcoholic fatty liver disease (NAFLD) with obesity and type 2 diabetes is very well established, it is only recently that studies have addressed other aspects of hepatic metabolism, particularly lipid fluxes and energy balance. Likewise, the clinical relevance of NAFLD has long been the subject of study. Given its role as a risk factor for hepatocellular carcinoma and cardiovascular diseases, a critical analysis of NAFLD pathophysiology, diagnostic procedures and therapeutic measures is vital to fight this common comorbidity of obesity and type 2 diabetes. The following series of mini-reviews summarises the contributions of leading researchers in this field presented at a symposium at the 51st EASD annual meeting in Stockholm in September 2015.
Literatur
1.
Zurück zum Zitat Koliaki C, Roden M (2013) Hepatic energy metabolism in human diabetes mellitus, obesity and non-alcoholic fatty liver disease. Mol Cell Endocrinol 379:35–42CrossRefPubMed Koliaki C, Roden M (2013) Hepatic energy metabolism in human diabetes mellitus, obesity and non-alcoholic fatty liver disease. Mol Cell Endocrinol 379:35–42CrossRefPubMed
2.
Zurück zum Zitat Titchenell PM, Chu Q, Monks BR, Birnbaum MJ (2015) Hepatic insulin signalling is dispensable for suppression of glucose output by insulin in vivo. Nat Commun 6:7078CrossRefPubMedPubMedCentral Titchenell PM, Chu Q, Monks BR, Birnbaum MJ (2015) Hepatic insulin signalling is dispensable for suppression of glucose output by insulin in vivo. Nat Commun 6:7078CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Koliaki C, Szendroedi J, Jelenik T et al (2015) Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver or steatohepatitis. Cell Metab 21:739–746CrossRefPubMed Koliaki C, Szendroedi J, Jelenik T et al (2015) Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver or steatohepatitis. Cell Metab 21:739–746CrossRefPubMed
4.
Zurück zum Zitat Jones JG (2016) Hepatic glucose and lipid metabolism. Diabetologia doi:10.1007/s00125-016-3940-5 Jones JG (2016) Hepatic glucose and lipid metabolism. Diabetologia doi:10.1007/s00125-016-3940-5
5.
Zurück zum Zitat European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) (2016) EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia doi:10.1007/s00125-016-3902-y European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD) and European Association for the Study of Obesity (EASO) (2016) EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia doi:10.​1007/​s00125-016-3902-y
7.
Zurück zum Zitat Anderwald C, Bernroider E, Krssak M et al (2002) Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. Diabetes 51:3025–3032CrossRefPubMed Anderwald C, Bernroider E, Krssak M et al (2002) Effects of insulin treatment in type 2 diabetic patients on intracellular lipid content in liver and skeletal muscle. Diabetes 51:3025–3032CrossRefPubMed
8.
Zurück zum Zitat Singh S, Khera R, Allen AM, Murad MH, Loomba R (2015) Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: a systematic review and network meta-analysis. Hepatology 62:1417–1432CrossRefPubMed Singh S, Khera R, Allen AM, Murad MH, Loomba R (2015) Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: a systematic review and network meta-analysis. Hepatology 62:1417–1432CrossRefPubMed
9.
Zurück zum Zitat Cusi K (2016) Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Diabetologia doi:10.1007/s00125-016-3952-1 Cusi K (2016) Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Diabetologia doi:10.​1007/​s00125-016-3952-1
10.
Zurück zum Zitat Armstrong MA, Gaunt P, Aithal GP et al (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387:679–690CrossRefPubMed Armstrong MA, Gaunt P, Aithal GP et al (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387:679–690CrossRefPubMed
11.
Zurück zum Zitat Perry RJ, Zhang D, Zhang XM, Boyer JL, Shulman GI (2015) Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats. Science 347:1253–1256CrossRefPubMedPubMedCentral Perry RJ, Zhang D, Zhang XM, Boyer JL, Shulman GI (2015) Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats. Science 347:1253–1256CrossRefPubMedPubMedCentral
Metadaten
Titel
The liver in focus
verfasst von
Michael Roden
Publikationsdatum
07.04.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Diabetologia / Ausgabe 6/2016
Print ISSN: 0012-186X
Elektronische ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-016-3911-x

Weitere Artikel der Ausgabe 6/2016

Diabetologia 6/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Neu im Fachgebiet Innere Medizin

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.